Corrective Phases R...
Health Care: Drugs
Cellceutix Corporation (CTIX: OTC)
$0.57 0.02 | 3.64%
06/01/12 - 03:58 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with CTIX
- Portfolio NameUser Type
Latest CTIX Headlines from TheStreet
- Cheap Tickets Up as Cendant Extends Share Offer Deadline 09.24.01 | 08:09 am
- Cheap Tickets Tumbles on Warning 06.26.01 | 11:06 am
- The Daily Interview: Online Travel Skies Getting Crowded 06.13.01 | 10:06 am
- Ticker-Tape Parade: Cendant Buys Cheap Tickets, Semis Get an Upgrade 12.31.69 | 07:12 pm
- Cheap Tickets Leaps on Offer From Cendant 12.31.69 | 07:12 pm
Press Releases for CTIX
- Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - PR Newswire 04.18.11 | 07:04 am
- Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting - PR Newswire 04.11.11 | 06:04 am
- Cellceutix Cancer Drug, Kevetrinâ¢, Shows Increased Levels Of P21; Biomarker For Cancer Trials - PR Newswire 03.31.11 | 08:03 am
- Cellceutix Announces That It Has Signed Confidential Disclosure Agreement For Its Autism Drug With Large Pharmaceutical Company - PR Newswire 03.28.11 | 07:03 am
- Cellceutix Anti-Cancer Breakthrough Selected For Poster Presentation At American Association For Cancer Research (AACR) - PR Newswire 03.21.11 | 07:03 am
- Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin⢠Has Begun - PR Newswire 03.14.11 | 06:03 am
- Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - PR Newswire 03.08.11 | 04:03 pm
- Cellceutix Discovers Drug Activates 'Guardian Angel P53' In Fight Against Leukemia - PR Newswire 03.07.11 | 07:03 am
- Cellceutix Cancer Drug Kevetrin⢠Shows No Genotoxicity In Study - PR Newswire 03.02.11 | 07:03 am
Partner Headlines for CTIX
